-- The treatment of more than 1 million patients worldwide with Edwards'
       heart valve repair and replacement technologies.

    -- The implantation of the Edwards SAPIEN transcatheter aortic heart valve
       in more than 1,000 patients worldwide through a series of extensive
       clinical trials and feasibility studies in Europe, the U.S. and Canada,
       as well as commercial sales in Europe.

    -- The start of patient enrollment for transcatheter aortic valve
       replacement procedures with the Ascendra transapical delivery system at
       participating sites in Edwards' U.S. pivotal trial of the Edwards
       SAPIEN valve.  Edwards has conditional approval from the U.S. Food and
       Drug Administration to perform procedures with both the Ascendra
       transapical delivery system and the RetroFlex transfemoral delivery
       system at the PARTNER trial sites.

    -- Regulatory and reimbursement approval received this week from the
       Japanese Ministry of Health for the Carpentier-Edwards PERIMOUNT Magna
       pericardial aortic heart valve. As the first and only device of its
       kind, this valve combines more than 20 years of clinical experience and
       innovation with the most advanced tissue engineering technologies.  The
       PERIMOUNT Magna valve is the best selling tissue valve in the world.


    New Products
    Edwards is also introducing and unveiling several new products at AATS:

    -- Edwards is offering new arterial and venous cannulae, which are the
       flexible tubes used to establish cardiopulmonary bypass in cardiac
       surgery.  The new cannulae are designed to reduce trauma, increase
       efficiency and provide a variety of cannulation site options that
       address today's more challenging surgical approach. Among these are the
       FemTrak femoral venous cannula and the OptiSite arterial cannula, which
       both have proprietary ultra-thin wall technology to help optimize blood
       flow while a patient is on a heart-lung machine.

    -- The next-generation of the Carpentier-Edwards Physio annuloplasty ring
       will be unveiled.  This product addresses the degenerative segment of
       mitral valve repair -- the largest segment within the repair market --
       and features a ring design that better conforms to the patient's
       natural anatomy.  The original Carpentier-Edwards Physio ring is the
       number-one global repair product and was launched in 1994.

    Sunday, May 11

    -- Session V, Percutaneous Aortic Valve Replacement: Update on
       Percutaneous AVR with Edwards SAPIEN Valve (retrograde and antegrade)
       -- 4:15 p.m. to 4:35 p.m.  Ballroom 20 A-C, San Diego Convention
       Center.  Presenter: John G. Webb, St. Paul's Hospital, Vancouver, BC,
       Canada.

    -- Session V, Percutaneous Aortic Valve Replacement: Identification of
       Appropriate Patients: Who Actually is "Inoperable"? -- 4:55 p.m. to
       5:15 p.m.  Ballroom 20 A-C, San Diego Convention Center.  Presenter:
       Michael J. Mack, Cardiothoracic Surgery Associates of North Texas,
       Dallas, TX.


    Wednesday, May 14

    -- Emerging Technologies and Techniques Forum: Is Transcatheter Based
       Aortic Valve Implantation Really Less Invasive than Minimal Invasive
       Aortic Valve Replacement? -- 7:13 a.m. to 7:26 a.m. Room 25, San Diego
       Convention Center. Presenters/authors: Mirko Doss, Sven Martens,
       Stephan Fichtelscherer, Thomas Trepels, Gerhard Wimmer Greinecker,
       Anton Moritz, Volker Schachinger, Thoracic and Cardiovascular Surgery,
       J.W. Goethe University Frankfurt, Frankfurt am Main, Germany.

    -- Emerging Technologies and Techniques Forum: Transapical Transcatheter
       Aortic Valve Implantation One Year Follow-Up in 19 Patients --
       8:05 a.m. to 8:18 a.m. Room 25, San Diego Convention Center.
       Presenters/authors: Jian Ye, Anson Cheung, John G. Webb, Daniel R.
       Wong, Ronald G. Carere, Christopher R. Thompson, Samuel V.
       Lichtenstein, Cardiothoracic Surgery, University of British Columbia,
       Vancouver, BC, Canada.